Non-immediate hypersensitivity reactions to iomeprol: Diagnostic value of skin tests and cross-reactivity with other iodinated contrast media.


Journal

Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028

Informations de publication

Date de publication:
12 2022
Historique:
revised: 28 05 2022
received: 24 01 2022
accepted: 10 06 2022
pubmed: 12 7 2022
medline: 1 12 2022
entrez: 11 7 2022
Statut: ppublish

Résumé

Iodinated contrast media produce non-immediate hypersensitivity reactions (NIHR). The goal of this prospective study was to determine the utility of skin tests and the subsequent tolerance to negative skin-tested iodinated contrasts in patients with NIHR caused by iomeprol. Prick and intradermal tests with iomeprol, iopamidol, iopromide, and iobitridol were performed in all patients. IV challenge with the causative contrast (iomeprol in 90%) was made if skin tests were negative. In case of a positive skin test with the causal contrast, or a positive challenge test with it, IV challenge test with an alternative, negative skin-tested contrast was performed in all patients. Skin tests were positive in 47.6% (20/42) of patients with NIHR induced by iomeprol. Of the 66 challenge tests performed with negative skin-tested iodinated contrasts, tolerance was confirmed in 35 (53%): 32 iomeron, 2 iobitridol, 1 iopamidol. Cross-reactivity between iomeprol and iopamidol was 22% (4/20 in patients with positive skin tests and 5/21 in patients with negative skin tests). Sensitivity of the skin tests was less than 50% NIHRs due to iomeprol, while the negative predictive value of skin tests in patients who tolerated challenges with alternative contrasts (mainly iopamidol) was 53% (35 tolerated out of 66 performed). The cross-reactivity between iomeprol and iopamidol is high.

Sections du résumé

BACKGROUND
Iodinated contrast media produce non-immediate hypersensitivity reactions (NIHR). The goal of this prospective study was to determine the utility of skin tests and the subsequent tolerance to negative skin-tested iodinated contrasts in patients with NIHR caused by iomeprol.
METHODS
Prick and intradermal tests with iomeprol, iopamidol, iopromide, and iobitridol were performed in all patients. IV challenge with the causative contrast (iomeprol in 90%) was made if skin tests were negative. In case of a positive skin test with the causal contrast, or a positive challenge test with it, IV challenge test with an alternative, negative skin-tested contrast was performed in all patients.
RESULTS
Skin tests were positive in 47.6% (20/42) of patients with NIHR induced by iomeprol. Of the 66 challenge tests performed with negative skin-tested iodinated contrasts, tolerance was confirmed in 35 (53%): 32 iomeron, 2 iobitridol, 1 iopamidol. Cross-reactivity between iomeprol and iopamidol was 22% (4/20 in patients with positive skin tests and 5/21 in patients with negative skin tests).
CONCLUSIONS
Sensitivity of the skin tests was less than 50% NIHRs due to iomeprol, while the negative predictive value of skin tests in patients who tolerated challenges with alternative contrasts (mainly iopamidol) was 53% (35 tolerated out of 66 performed). The cross-reactivity between iomeprol and iopamidol is high.

Identifiants

pubmed: 35815908
doi: 10.1111/all.15433
doi:

Substances chimiques

iomeprol 17E17JBP8L
Iopamidol JR13W81H44
Contrast Media 0
iobitridol 182ECH14UH
Iodine Compounds 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3641-3647

Informations de copyright

© 2022 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

Références

Torres MJ, Gomez F, Doña I, et al. Diagnostic evaluation of patients with nonimmediate cutaneous hypersensitivity reactions to iodinated contrast media. Allergy. 2012;67:929-935.
Torres MJ, Trautmann A, Böhm I, et al. Practice parameters for diagnosing and managing iodinated contrast media hypersensitivity. Allergy. 2021;76:1325-1339.
Rosado Ingelmo A, Doña Diaz I, Cabañas Moreno R, et al. Clinical practice guidelines for diagnosis and management of hypersensitivity reactions to contrast media. J Investig Allergol Clin Immunol. 2016;26:144-155.
Kanny G, Pichler W, Morisset M, et al. T-cell mediated reactions to iodinated contrast media. Evaluation by skin and lymphocyte activation tests. J Allergy Clin Immunol. 2005;115:179-185.
Torres MJ, Mayorga C, Cornejo-García JA, et al. Monitoring non-immediate allergic reactions to iodine contrast media. Clin Exp Immunol. 2008;152:233-238.
Yoon SH, Lee SY, Kang HR, et al. Skin tests in patients with hypersensitivity reaction to iodinated contrast media: a meta-analysis. Allergy. 2015;70(6):625-637.
Lerondeau B, Trechot P, Waton J, et al. Analysis of cross-reactivity among radiocontrast media in 97 hyper-sensitivity reactions. J Allergy Clin Immunol. 2016;137:633-635.
Brockow K, Romano A, Aberer W, et al. Skin testing in patients with hypersensitivity reactions to iodinated contrast media - a European multicenter study. Allergy. 2009;64:234-241.
Schrijvers S, Breynaert C, Ahmedali Y, Bourrain JL, Demoly P, Chiriac AM. Skin testing for suspected iodinated contrast media hypersensitivity. J Allergy Clin Immunol Pract. 2018;6:1246-1254.
Sánchez-Borges M, Aberer W, Brockow K, et al. Controversies in drug allergy: radiographic contrast media. J Allergy Clin Immunol Pract. 2019;7:61-65.
Heinzerling LM, Tomsitz D, Anliker MD. Is drug allergy less prevalent than previously assumed? A 5-year analysis. Br J Dermatol. 2012;106:107-114.
Webb JA, Stacul F, Thomsen HS, Morcos SK. Late adverse reactions to intravascular iodinated contrast media. Eur Radiol. 2003;13:181-184.
Gaudin O, Deschamps O, Duang TA, et al. Cutaneous tests and interest of iobitridol in non-immediate hypersensitivity to contrast media: a case series of 43 patients. JEADV. 2020;34(4):e178-e180.
Gracia-Bara MT, Moreno E, Laffond E, et al. Tolerability of iobitridol in patients with non-immediate hypersensitivity reactions to iodinated contrast media. Allergy. 2019;74:195-197.
Trcka J, Schmidt C, Seitz CS, Brocker EB, Gross GE, Trautmann A. Anaphylaxis to iodinated contrast material: nonallergic hypersensitivity or IgE-mediated allergy? Am J Roentgenol. 2008;190(3):666-670.
Trautmann A, Brockow K, Behle V, Stoevesandt J. Radiocontrast media hypersensitivity: skin testing differentiates allergy from nonallergic reactions and identifies a safe alternative as proven by intravenous provocation. J Allergy Clin Immunol Pract. 2019;7(7):2218-2224.
Hasdenteufel F, Waton J, Cordebar V, et al. Delayed hypersensitivity reactions caused by iodixanol: an assessment of cross-reactivity in 22 patients. J Allergy Clin Immunol. 2011;128:1356-1357.
Vernassière C, Trechot P, Commun N, Schmutz JL, Barbaud A. Low negative predictive value of skin tests in investigating delayed reactions to radio-contrast media. Contact Dermatitis. 2004;50:359-366.

Auteurs

Pedro Gamboa (P)

Servicio de Alergia, Hospital Universitario Cruces, Barakaldo, Spain.
Biocruces Bizkaia Health Research Institute, Immunopathology Group, Barakaldo, Spain.

Javier Sánchez de Vicente (J)

Servicio de Alergia, Hospital Universitario Cruces, Barakaldo, Spain.
Biocruces Bizkaia Health Research Institute, Immunopathology Group, Barakaldo, Spain.

Cristina Galán (C)

Servicio de Alergia, Hospital Universitario Cruces, Barakaldo, Spain.

Ignacio Jáuregui (I)

Servicio de Alergia, Hospital Universitario Cruces, Barakaldo, Spain.
Biocruces Bizkaia Health Research Institute, Immunopathology Group, Barakaldo, Spain.

Aritza Segurola (A)

Servicio de Alergia, Hospital Universitario Cruces, Barakaldo, Spain.
Biocruces Bizkaia Health Research Institute, Immunopathology Group, Barakaldo, Spain.

Eduardo García-Lirio (E)

Servicio de Alergia, Hospital Universitario Cruces, Barakaldo, Spain.
Biocruces Bizkaia Health Research Institute, Immunopathology Group, Barakaldo, Spain.

Yolanda Seras (Y)

Servicio de Alergia, Hospital Universitario Cruces, Barakaldo, Spain.
Biocruces Bizkaia Health Research Institute, Immunopathology Group, Barakaldo, Spain.

Mª Dolores Martínez-Antón (MD)

Servicio de Alergia, Hospital Universitario Cruces, Barakaldo, Spain.
Biocruces Bizkaia Health Research Institute, Immunopathology Group, Barakaldo, Spain.

Angel Arrien de Lecea (A)

Servicio de Alergia, Hospital Universitario Cruces, Barakaldo, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH